Hello Heart, a leading digital hypertension program, completed a $12M Series B led by Khosla Ventures, adding to Khosla’s portfolio of AI and health investments.
“Every consumer should be the CEO of their own health. Hello Heart is one of the only digital health solutions in hypertension that we have seen that has the potential to move the needle on population health and in delivering long term clinical impact. We are very excited to be a part of their journey,” said Vinod Khosla, Managing Partner of Khosla Ventures
Hello Heart’s mission is to empower people to manage and improve their health using technology. The company’s flagship solution helps patients manage blood pressure, sugar levels, medications and activity using AI-technology. Patients manage their health from their smartphone, receive personalized explanations for their results, and improve their health with clinically based tips; all without needing to talk to a live coach over the phone or in person.
“Our mission is to empower patients to understand and improve their health, and we’re very proud to be able to help them do it so effectively in heart health – #1 cause of death in the world. We’re in an exciting growth phase and are now scaling up our sales team in the employers and health plan space,” said Maayan Cohen, CEO of Hello Heart.
Hello Heart is the only hypertension smartphone solution on the market with a peer-reviewed clinical study on blood pressure outcomes. The program is offered by many large employers and has been endorsed by the NBGH Innovation Board. The company recently received the Impact Award for outstanding clinical outcomes in population management by the EHIR Group.
In a retrospective peer-reviewed study performed by researchers from UCLA and Harvard Medical School, 70% of users reduced their blood pressure and the average decrease of systolic blood pressure was 22 mmHg. These clinical results are 2X-3X times higher than the best results ever documented in a clinical study, including studies published by Hello Heart’s digital competitors.
Dr. Eyal Zimlichman a Harvard Medical School faculty researcher, and the Chief Medical and Innovation Officer of Sheba Medical Center led the research. “Delivering clinical outcomes at the scale of population health requires strong patient engagement across a variety of patient types. Hello Heart’s ability to drive engagement is what led to these unprecedented results” explains Dr. Zimlichman.
Some notable investments from Khosla include: Square, Stripe, Instacart, DoorDash, Ginger, AliveCore, and Impossible Foods. Previous investors include BlueRun Ventures, who led the company’s Series A round in 2017, along with Maven Ventures and Resolute Ventures which also participated in the round.